MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults

NACompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

May 30, 2022

Study Completion Date

May 30, 2022

Conditions
Treatment-resistant Depression (TRD)
Interventions
BEHAVIORAL

Mindfulness-Based Cognitive Therapy (MBCT)

A group intervention delivered by a psychiatrist and two assistants. Sessions were 120 minutes, once per week, for 12 weeks. Content included mindfulness exercises such as 3-minute breathing space, body scanning, mindfulness walking, meditation, and cognitive therapy techniques to observe connections between thoughts, emotions, and behavior.

DRUG

Escitalopram Hydrobromide

Oral administration of escitalopram hydrobromide tablets, 20mg once daily (qd) for the entire 12-week study duration.

Trial Locations (1)

063000

Tangshan Gongren Hospital, Tangshan

All Listed Sponsors
lead

Yun Zhang

OTHER

NCT07077291 - MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults | Biotech Hunter | Biotech Hunter